Difference between revisions of "Dey N, et al. Pharmacol. Ther. (2017) cited as Ref 362 in DOI: 10.1038/s41392-020-0110-5 (Q9625)"
Jump to navigation
Jump to search
(Created a new Item: #quickstatements; #temporary_batch_1589975872009) |
(Created claim: Page(s) (P105): 91-106, #quickstatements; #temporary_batch_1590074839150) |
||||||||||||||
| (10 intermediate revisions by the same user not shown) | |||||||||||||||
| Property / First Author string | |||||||||||||||
| + | Dey N | ||||||||||||||
| Property / First Author string: Dey N / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Second Author string | |||||||||||||||
| + | De P | ||||||||||||||
| Property / Second Author string: De P / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Third Author string | |||||||||||||||
| + | Leyland-Jones B | ||||||||||||||
| Property / Third Author string: Leyland-Jones B / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / DOI Identifier | |||||||||||||||
| + | |||||||||||||||
| Property / DOI Identifier: 10.1016/j.pharmthera.2017.02.037 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / PubMed ID | |||||||||||||||
| + | |||||||||||||||
| Property / PubMed ID: 28216025 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2017
| ||||||||||||||
| Property / Publication Date: 2017 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Published In Name String | |||||||||||||||
| + | Pharmacol. Ther. | ||||||||||||||
| Property / Published In Name String: Pharmacol. Ther. / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Volume | |||||||||||||||
| + | 175 | ||||||||||||||
| Property / Volume: 175 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / title | |||||||||||||||
| + | PI3K-AKT-mTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials (English) | ||||||||||||||
| Property / title: PI3K-AKT-mTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials (English) / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Page(s) | |||||||||||||||
| + | 91-106 | ||||||||||||||
| Property / Page(s): 91-106 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| links / sliswiki / name | links / sliswiki / name | ||||||||||||||
| + | |||||||||||||||
Latest revision as of 15:39, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Dey N, et al. Pharmacol. Ther. (2017) cited as Ref 362 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Dey N
0 references
De P
0 references
Leyland-Jones B
0 references
2017
0 references
Pharmacol. Ther.
0 references
175
0 references
PI3K-AKT-mTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials (English)
0 references
91-106
0 references
